Abraxis Pharmaceutical Products Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Abraxis Pharmaceutical Products (APP), the hospital-based business of Abraxis BioScience, Inc. (NASDAQ:ABBI), today announced the approval from the U.S. Food and Drug Administration (FDA) to market Cefotetan Disodium for Injection, the generic equivalent of AstraZeneca’s Cefotan®. Cefotetan has the longest half-life of any first or second generation cephalosporin and offers surgeons a convenient single-dose option for surgical prophylaxis and secondary infections. APP, now as the only supplier of this drug, expects to launch this important anti-infective back into the market this month. Based on previous IMS data, Cefotetan has market potential in excess of $40 million.